Core Insights - Idorsia Ltd announced the publication of a new analysis from the Phase 3 PRECISION study, highlighting the effects of aprocitentan on blood pressure variables in resistant hypertension [1][6] Company Overview - Aprocitentan (TRYVIO™/JERAYGO™) is the first approved antihypertensive targeting the endothelin pathway, showing significant reductions in 24-hour blood pressure, especially at night [2][7] - Aprocitentan is approved in the US and EU for treating resistant hypertension in combination with other antihypertensives, with commercial availability since October 2024 [7][24] Clinical Findings - The PRECISION study demonstrated that aprocitentan led to substantial improvements in ambulatory blood pressure parameters predictive of cardiovascular risk, potentially reducing cardiovascular events [3][10] - Aprocitentan treatment normalized dipping patterns in non-dippers and reduced blood pressure load by approximately 20% during both daytime and nighttime [11][13] - The drug's efficacy was consistent across patients with varying arterial stiffness and salt sensitivity, indicating its broad applicability in difficult-to-control hypertension [11][12] Market Context - Approximately 1.4 billion people globally suffer from hypertension, with many patients remaining uncontrolled despite multiple treatments [5][9] - In the US, around 50% of patients with hypertension on multiple therapies do not achieve blood pressure control, highlighting a significant medical need [5][9] Research and Development - The PRECISION study was a multicenter, randomized, double-blind trial involving 730 patients, assessing the efficacy of aprocitentan against placebo [8][10] - The study's primary endpoints included changes in office systolic blood pressure, with significant reductions observed in both the 12.5 mg and 25 mg doses of aprocitentan compared to placebo [10][12] Safety Profile - Treatment-emergent adverse events were reported in 27.6% and 36.7% of patients treated with aprocitentan 12.5 mg and 25 mg, respectively, with fluid retention being the most common side effect [14]

New analysis from landmark Phase 3 PRECISION trial published in the Journal of Hypertension highlights aprocitentan led to improvements in dipping pattern and BP load Findings reinforce the role of aprocitentan’s novel endothelin pathway mechanism in addressing significant medical need in difficult-to-control hypertension Allschwil, Switzerland – November 10, 2025Idorsia Ltd (SIX: IDIA) announced the publication of a new analysis from the landmark Phase 3 PRECISION study in the Journal of Hypertension title ...